Opportunities in metabolic engineering to facilitate scalable alkaloid production
Numerous drugs and drug precursors in the current pharmacopoeia originate from plant sources. The limited yield of some bioactive compounds in plant tissues, however, presents a significant challenge for large-scale drug development. Metabolic engineering has facilitated the development of plant cel...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Nature Publishing Group
2012
|
| Online Access: | http://hdl.handle.net/1721.1/68707 https://orcid.org/0000-0003-0437-3157 |
| _version_ | 1811080830102011904 |
|---|---|
| author | Leonard, Effendi Runguphan, Weerawat O'Connor, Sarah Ellen Prather, Kristala L. Jones |
| author2 | Massachusetts Institute of Technology. Department of Chemical Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Chemical Engineering Leonard, Effendi Runguphan, Weerawat O'Connor, Sarah Ellen Prather, Kristala L. Jones |
| author_sort | Leonard, Effendi |
| collection | MIT |
| description | Numerous drugs and drug precursors in the current pharmacopoeia originate from plant sources. The limited yield of some bioactive compounds in plant tissues, however, presents a significant challenge for large-scale drug development. Metabolic engineering has facilitated the development of plant cell and tissue systems as alternative production platforms that can be scaled up in a controlled environment. Nevertheless, effective metabolic engineering approaches and the predictability of genetic transformations are often obscured due to the myriad cellular complexities. Progress in systems biology has aided the understanding of genome-wide interconnectivities in plant-based systems. In parallel, the bottom-up assembly of plant biosynthetic pathways in microorganisms demonstrated the possibilities of a new means of production. In this Perspective, we discuss the opportunities and challenges of implementing metabolic engineering in various platforms for the synthesis of natural and unnatural plant alkaloids. |
| first_indexed | 2024-09-23T11:37:33Z |
| format | Article |
| id | mit-1721.1/68707 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T11:37:33Z |
| publishDate | 2012 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | mit-1721.1/687072022-10-01T04:51:37Z Opportunities in metabolic engineering to facilitate scalable alkaloid production Leonard, Effendi Runguphan, Weerawat O'Connor, Sarah Ellen Prather, Kristala L. Jones Massachusetts Institute of Technology. Department of Chemical Engineering Massachusetts Institute of Technology. Department of Chemistry Prather, Kristala L. Jones Leonard, Effendi Runguphan, Weerawat O'Connor, Sarah Ellen Prather, Kristala L. Jones Numerous drugs and drug precursors in the current pharmacopoeia originate from plant sources. The limited yield of some bioactive compounds in plant tissues, however, presents a significant challenge for large-scale drug development. Metabolic engineering has facilitated the development of plant cell and tissue systems as alternative production platforms that can be scaled up in a controlled environment. Nevertheless, effective metabolic engineering approaches and the predictability of genetic transformations are often obscured due to the myriad cellular complexities. Progress in systems biology has aided the understanding of genome-wide interconnectivities in plant-based systems. In parallel, the bottom-up assembly of plant biosynthetic pathways in microorganisms demonstrated the possibilities of a new means of production. In this Perspective, we discuss the opportunities and challenges of implementing metabolic engineering in various platforms for the synthesis of natural and unnatural plant alkaloids. National Science Foundation (U.S.) (grant no. 0540879) Synthetic Biology Engineering Research Center Massachusetts Institute of Technology. Energy Initiative (Grant 6917278) National Institutes of Health (U.S.) (GM074820) National Science Foundation (U.S.) (MCB-0719120) 2012-01-30T16:41:27Z 2012-01-30T16:41:27Z 2009-04 Article http://purl.org/eprint/type/JournalArticle 1552-4450 1552-4469 http://hdl.handle.net/1721.1/68707 Leonard, Effendi et al. “Opportunities in metabolic engineering to facilitate scalable alkaloid production.” Nature Chemical Biology 5.5 (2009): 292-300. https://orcid.org/0000-0003-0437-3157 en_US http://dx.doi.org/10.1038/nchembio.160 Nature Chemical Biology Creative Commons Attribution-Noncommercial-Share Alike 3.0 http://creativecommons.org/licenses/by-nc-sa/3.0/ application/pdf Nature Publishing Group Prof. Prather via Erja Kajosalo |
| spellingShingle | Leonard, Effendi Runguphan, Weerawat O'Connor, Sarah Ellen Prather, Kristala L. Jones Opportunities in metabolic engineering to facilitate scalable alkaloid production |
| title | Opportunities in metabolic engineering to facilitate scalable alkaloid production |
| title_full | Opportunities in metabolic engineering to facilitate scalable alkaloid production |
| title_fullStr | Opportunities in metabolic engineering to facilitate scalable alkaloid production |
| title_full_unstemmed | Opportunities in metabolic engineering to facilitate scalable alkaloid production |
| title_short | Opportunities in metabolic engineering to facilitate scalable alkaloid production |
| title_sort | opportunities in metabolic engineering to facilitate scalable alkaloid production |
| url | http://hdl.handle.net/1721.1/68707 https://orcid.org/0000-0003-0437-3157 |
| work_keys_str_mv | AT leonardeffendi opportunitiesinmetabolicengineeringtofacilitatescalablealkaloidproduction AT runguphanweerawat opportunitiesinmetabolicengineeringtofacilitatescalablealkaloidproduction AT oconnorsarahellen opportunitiesinmetabolicengineeringtofacilitatescalablealkaloidproduction AT pratherkristalaljones opportunitiesinmetabolicengineeringtofacilitatescalablealkaloidproduction |